Table 3 Combination agents of FAK inhibitors
From: Focal adhesion kinase: from biological functions to therapeutic strategies
Name | Alternative names | Target(s) | Combination agents | Preclinical trials | Clinical trials | ||
|---|---|---|---|---|---|---|---|
Cancer types | References | Cancer types | NCT number | ||||
VS-6063 | Defactinib, PF-04554878 | FAK, Pyk2 | Pembrolizumab (a PD1 inhibitor) | – | – | NSCLC, mesothelioma, pancreatic tumor | NCT02758587 |
– | – | PDAC | NCT03727880 | ||||
– | – | Solid tumor, PDAC | NCT02546531 | ||||
VS-6766 (a RAF/MEK inhibitor) | – | – | NSCLC, ovarian cancer, endometrioid carcinoma, pancreatic cancer | NCT03875820 | |||
– | – | Metastatic uveal melanoma | NCT04720417 | ||||
Paclitaxel | Ovarian cancer | [189] | Ovarian cancer | NCT01778803 | |||
Pancreatic cancer | [156] | Ovarian cancer | NCT03287271 | ||||
Gemcitabine | Lung cancer | [185] | Solid tumor, pancreatic cancer | NCT02546531 | |||
VS-5584 NCT00835679 (a PI3K inhibitor) | – | – | Relapsed malignant mesothelioma | NCT02372227 | |||
Radiation therapy | Pancreatic cancer | [184] | Pancreas cancer | NCT04331041 | |||
Cetuximab | – | – | CRC | NCT00835679 | |||
BRD4 inhibitor | lung cancer | [186] | – | – | |||
EGFR-TKI | Lung cancer | [187] | – | – | |||
Docetaxel | Prostate cancer | [188] | – | – | |||
BI 853520 | IN10018, ifebemtinib | FAK | Albumin-bound paclitaxel, gemcitabine, KN046 | – | – | Pancreatic cancer | NCT05827796 |
Cobimetinib, atezolizumab | – | – | Metastatic melanoma | NCT04109456 | |||
PLD | – | – | Platinum-resistant ovarian cancer | NCT05551507 | |||
PLD, toripalimab | – | – | Locally advanced or metastatic solid tumor | NCT05830539 | |||
Docetaxel | – | – | Gastric cancer | NCT05327231 | |||
D-1553 | – | – | Solid tumor | NCT05379946 | |||
KRAS G12C inhibitors | CRC, pancreatic cancer, NSCLC | [145] | – | – | |||
Radiation therapy | Pancreatic cancer | [162] | – | – | |||
Paclitaxel | Ovarian cancer | [194] | – | – | |||
VS-6062 | PF-562,271 | FAK, Pyk2 | Gemcitabine | Pancreatic cancer | [112] | – | – |
Sunitinib | Hepatocellular cancer | [179] | – | – | |||
anti-VEGF | Ovarian cancer | [182] | – | – | |||
AZD-1152 | Ewing sarcoma | [183] | – | – | |||
VS-4718 | PND-1186 | FAK, Pyk2 | Nab-paclitaxel, gemcitabine | – | – | Pancreatic cancer | NCT02651727 |
Gemcitabine, adoptive cell transfer (ACT), Anti-PD1/anti-CTLA4 | Pancreatic cancer | [123] | – | – | |||
GSK2256098 | – | FAK | Trametinib (a MEK inhibitor) | – | – | Advanced solid tumor | NCT01938443 |
Pazopanib | Ovarian cancer | [205] | – | – | |||
CT-707 | Conteltinib | FAK, ALK, Pyk2 | Toripalimab, gemcitabine | – | – | Advanced pancreatic cancer | NCT05580445 |
TAE226 | NVP-226 | FAK, IGF-IR | Radiation therapy | Glioma | [201] | – | – |